MedPath

Comparative Study Menaquinone-7

Not Applicable
Completed
Conditions
Bioavailability
Registration Number
NCT01873274
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The objective of this study is to investigate the absorption of menaquinone-7 from a nutrient-enriched dairy product compared to a general dairy product enriched with menaquinone-7 and a menaquinone-7-containing supplement.

Detailed Description

In an earlier study, beneficial effects of a nutrient-enriched dairy product on vitamin K-status were observed. The study product contained menaquinone-7 (MK-7) and omega-3 fatty acids for vascular health and extra minerals and antioxidants to support general health. It was the first time that such low dose of MK-7 (50 µg) could significantly improve vascular and general vitamin K-status already after short-term treatment. From the results of this study, it was assumed that the matrix of the dairy product and/or other components in the product, in which the vitamin was offered, contributed to optimal absorption and availability of vitamin K2. In this new study, the uptake and efficacy of MK-7 from the nutrient enriched product is investigated and compared to the uptake and efficacy from a MK-7-containing supplement and a basic dairy product enriched with MK-7.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
107
Inclusion Criteria
  • Apparently healthy men and postmenopausal women between 45 and 65 years old
  • Subjects with body weight and height according to BMI between 20 and 30 kg/m2
  • Subjects of Caucasian race
  • Subject has given written consent to take part in the study
Exclusion Criteria
  • Subjects with hypertension
  • Subjects with hypercholesterolemia
  • Subjects with (a history of) metabolic or gastrointestinal disease
  • Subjects presenting chronic degenerative and/or inflammatory disease
  • Subjects with (a history) of diabetes mellitus
  • Abuse of drugs and/or alcohol
  • Subjects receiving corticosteroid treatment
  • Subjects using oral anticoagulants and subjects with clotting disorders
  • Subjects using blood pressure-lowering medication
  • Subjects using cholesterol-lowering medication
  • Subjects using multivitamins or vitamin K supplements
  • Subjects consuming high amounts of vitamin K-containing food products
  • Subjects with cow's milk allergy and lactose intolerance

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The change in plasma MK-7 concentration after intervention between the three study groupsbaseline and 6 weeks
Secondary Outcome Measures
NameTimeMethod
The change in circulating markers of vitamin K-status, undercarboxylated osteocalcin and desphospho-uncarboxylated matrix Gla-protein, after intervention between the three study groups.baseline and 6 weeks

Trial Locations

Locations (1)

VitaK BV / Maastricht University Medical Center

🇳🇱

Maastricht, Netherlands

VitaK BV / Maastricht University Medical Center
🇳🇱Maastricht, Netherlands

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.